Form 4: Hinge Health CFO Sells $465K in Stock Under 10b5-1 Plan

Hinge Health's CFO, James Budge, sold a total of 11,006 shares of Class A Common Stock on March 23, 2026, under a pre-arranged 10b5-1 trading plan.

Summary

• James Budge, Chief Financial Officer of Hinge Health, Inc. (HNGE), reported the sale of Class A Common Stock.
• The transactions occurred on March 23, 2026.
• A total of 11,006 shares were sold across three separate transactions.
• The sales were executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Budge on June 12, 2025.
• The shares were sold at weighted average prices of $41.2858, $42.4514, and $42.8023 per share, totaling approximately $465,081.
• Following these transactions, Mr. Budge directly beneficially owns 401,427 shares of Class A Common Stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event because the sales were conducted under a pre-arranged 10b5-1 trading plan, which typically indicates a planned liquidity event rather than a reaction to new material information.

Negatives

• An officer selling shares, even under a 10b5-1 plan, can sometimes be perceived by some investors as a lack of confidence in the company's near-term stock price performance.

Future Outlook

There are no forward-looking statements or guidance provided in this filing.

Industry Context

StockSavvy.ai notes that insider sales, particularly by high-ranking executives like a CFO, are closely watched by the market. While sales under a Rule 10b5-1 plan indicate a pre-scheduled transaction designed to avoid accusations of trading on material non-public information, investors often scrutinize the timing and volume of such sales for any potential signals regarding management's long-term outlook or personal financial planning.

Stakeholder Impact

• Shareholders: May interpret the sale as a signal, though the 10b5-1 plan mitigates immediate concerns about insider sentiment.

Key Dates

Recommendation

The sale of shares by the CFO, while significant in volume, was executed under a pre-established Rule 10b5-1 trading plan. This suggests a planned personal liquidity event rather than a reaction to new negative company developments. Therefore, it does not provide a strong signal to alter an investment position based solely on this transaction. Investors should continue to monitor Hinge Health's operational performance and broader market conditions.

Keywords

Hinge Health, HNGE, James Budge, CFO, Form 4, Insider Trading, Stock Sale, 10b5-1 Plan, Equity Transaction, Corporate Officer